Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in option and evaluation dealmaking

2.1. Introduction
2.2. Difference between option and evaluation deals
2.2.1. Types of option agreement
2.3. Trends in option and evaluation deals since 2014
2.3.1. Option and evaluation dealmaking by year since 2014
2.3.2. Option and evaluation dealmaking by phase of development since 2014
2.3.3. Option and evaluation dealmaking by industry sector since 2014
2.3.4. Option and evaluation dealmaking by therapy area since 2014
2.3.5. Option and evaluation dealmaking by technology type since 2014
2.3.6. Option and evaluation dealmaking by most active company since 2014
2.4. Option-based deals
2.4.1. Attributes of option-based deals
2.4.2. Reasons for entering an option-based deal
2.4.3. Uptake of option exercise
2.4.4.The future of option-based deals
2.5. Co-promotion options
2.5.1. Attributes of co-promotion in multi-component deals
2.5.2. Reasons for including co-promotion options in a deal
2.5.3. Uptake of co-promotion rights
2.5.4. Co-promotion rights as bargaining chips
2.5.5. The future of co-promotion as part of multicomponent deals
2.6. Company acquisition options
2.6.1. Case study 1: Cephalon – Ception
2.6.2. Case study 2: Endo – Indevus
2.6.3. The future of option to acquire deals

Chapter 3 – Overview of option and evaluation deal structure

3.1. Introduction
3.2. Option and evaluation agreement structure
3.2. Example evaluation agreements
3.2.1.a. Case study 3: Idenix Pharmaceuticals – Janssen Pharmaceuticals
3.3. Option agreement structure
3.3.1. Example option agreements
3.3.1.a. Option to license
Case study 4: Biogen Idec – Isis Pharmaceuticals
3.3.1.b. Option to extend/expand applications/territories
Case study 5: Novartis –Prometheus
3.3.1.c. Option to finance
Case study 6: Amarantus BioSciences– Power3 Medical Products
3.3.1.d. Option to co-promote
Case study 7: Teva – OncoGenex Pharmaceuticals
3.3.1.e. Option to manufacture/supply
Case study 8: NPS Allelix – Nycomed
3.4. Option to acquire agreement structure
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 9: ViroPharma– Meritage Pharma
3.4.1.b. Case study 10: Nuvasive – Progentix Orthobiology

Chapter 4 – Leading option and evaluation deals

4.1. Introduction
4.2. Top option and evaluation deals by value

Chapter 5 – Top 25 most active option and evaluation dealmakers

5.1. Introduction
5.2. Top 25 most active option and evaluation dealmakers

Chapter 6 – Option and evaluation contracts directory

6.1. Introduction
6.2. Option andevaluation deals with contracts since 2014

Appendices

Appendix 1 – Option and evaluation dealmaking by companies A-Z
Appendix 2 – Option and evaluation dealmaking by industry sector
Appendix 3 – Option and evaluation dealmaking by stage of development
Appendix 4 – Option and evaluation dealmaking by therapy area
Appendix 5 – Option and evaluation dealmaking by technology type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

TABLE OF FIGURES

Figure 1: Definition of option and evaluation deals
Figure 2: Types of option right
Figure 3: Trends in option and evaluation deal announcements since 2014
Figure 4: Option and evaluation deals signed at each phase of development since 2014
Figure 5: Option and evaluation deals by industry sector since 2014
Figure 6: Option and evaluation deals by therapy area since 2014
Figure 7: Option and evaluation deals by technology type since 2014
Figure 8: Top 25 most active option and evaluation dealmakers since 2014
Figure 9: Example deals where co-promotion options have been actively exercised since 2000
Figure 10: Recent ?option to acquire’ deals
Figure 11: Components of the option and evaluation deal structure
Figure 12: Types of option in an agreement
Figure 13: Attributes of option terms
Figure 14: Top option and evaluation deals by value since 2014
Figure 15: Most active option and evaluation dealmakers since 2014